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Sepsis is at present one of the leading causes of morbidity and mortality in the neonatal population. Together with inflammation,
oxidative stress is involved in detrimental pathways activated during neonatal sepsis, eventually leading to organ dysfunction and
death. The redox cascade during sepsis is mainly initiated by IL-6 and IL-8 stimulation in newborns and includes multiple noxious
processes, as direct cell damage induced by reactive oxygen species, activation of gene expression leading to amplification of
inflammation and oxidative stress, and impairment of mitochondrial function. Once proinflammatory and prooxidant pathways
are established as stimulated by causing pathogens, self-maintaining unfavorable redox cycles ensue, leading to oxidative stress-
related cellular damage, independently from the activating pathogens themselves. Despite antioxidant systems are induced
during neonatal sepsis, as an adaptive response to an increased oxidative burden, a condition of redox imbalance favoring
oxidative pathways occurs, resulting in increased markers of oxidative stress damage. Therefore, antioxidant treatment would
exert beneficial effects during neonatal sepsis, potentially interrupting prooxidant pathways and preventing the maintenance of
detrimental redox cycles that cannot be directly affected by antibiotic treatment. Among others, antioxidant agents investigated
in clinical settings as adjunct treatment for neonatal sepsis include melatonin and pentoxifylline, both showing promising
results, while novel antioxidant molecules, as edaravone and endothelin receptor antagonists, are at present under investigation
in animal models. Finally, mitochondria-targeted antioxidant treatments could represent an interesting line of research in the
treatment of neonatal sepsis.
1. Introduction
Despite general improvement in intensive care of acutely
ill newborns, sepsis is still among the leading causes of
death in the neonatal population worldwide [1]. On a
whole, neonatal sepsis was reported to occur in 1 every
1000 live births [2]; however, incidence as high as 3% to
20% were reported in the population of preterm new-
borns, due to the presence of multiple coexisting risk
factors for nosocomial sepsis [3]. Mortality due to neo-
natal sepsis is strictly dependent on the causative patho-
gen and on the gestational age of the patients, with a
mortality rate as high as 20% observed in very preterm
newborns [2, 3].
According to the guidelines of the International Pediatric
Sepsis Consensus Conference, neonatal sepsis is defined as a
clinical syndrome characterized by the presence of both
infection and systemic inflammatory response syndrome
(SIRS) [4, 5]. SIRS includes inadequate core temperature
stability, tachycardia or bradycardia, tachypnea or unex-
plained need for mechanical ventilation, and leukocyte count
elevated or depressed for postnatal age [4]. It is at present
widely accepted that the infective insult due to the invasion
of sterile tissues by pathogens merely represents the initiation
of sepsis, while the process leading to the sepsis syndrome is
subsequently maintained by a cascade of inflammatory and
oxidative mechanisms that, once activated, act independently
from the presence of the pathogens themselves [6].
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It was demonstrated that, at least in adults, the immune
system shows a typical two-phase response during sepsis,
characterized by an initial increase of proinflammatory
mediators followed by a shift towards anti-inflammatory
cytokines, anergy of T-cells, and also apoptosis-induced loss
of cells of the adaptive immune system in the most severe
cases [7]. Activation of the immune system during sepsis is
paralleled by a complex chain of redox events in both adults
[8] and newborns [9], which partially differ among the two
populations. The redox cascade initiated by immune activa-
tion includes generation of consistent amount of reactive
oxygen species (ROS) and reactive nitrogen species (RNS),
activation of DNA transcription processes, and mitochon-
drial functional impairment, eventually leading to multiple
organ dysfunction and death [8, 9].
2. Redox Status in Neonatal Sepsis
2.1. The Redox Sepsis Cascade. While tumor necrosis factor-
alpha (TNF-alpha) plays a pivotal role in the onset of adult
sepsis [8], interleukin- (IL-) 6 and IL-8 represent the cyto-
kines mainly involved in the initiation of the sepsis cascade
in the newborn [9]. Levels of IL-6 and IL-8 are significantly
increased in septic newborns in comparison to healthy
controls, in both early-onset (EOS) and late-onset sepsis
(LOS) [10, 11] at least for the first 12–24 hours from the onset
of sepsis [10], and were proposed as useful markers for the
early diagnosis of sepsis in newborns in experimental set-
tings, and, when available, also in clinical practice [11, 12].
However, recent evidences suggest that the cytokines expres-
sion profile may consistently differ among septic newborns,
according to the timing of sepsis presentation and to the
patients’ gestational age. In a small cohort of term and late
preterm newborns, TNF-alpha increased in both EOS and
LOS in comparison to healthy controls, but only patients
with LOS showed also increased levels of IL-6 and IL-10
[13]. Moreover, while proinflammatory cytokines as TNF-
alpha and IL-6 were upregulated in the acute phase of
sepsis, anti-inflammatory cytokines as IL-4 and IL-10 were
preferentially overexpressed during the subacute phase [13],
providing evidence that the two-phase immune response,
typical of adult sepsis, would likely occur also in newborns.
The comparison of immune response during sepsis in pre-
term newborn≥ 32 or <32 weeks of gestational age showed
that mediators of innate immune response, as C-reactive
protein (CRP) and SC5b-9, are increased in both groups,
but proinflammatory cytokines as interferon-gamma, TNF-
alpha, and IL-6 are upregulated only in the subgroup with
gestational age≥ 32 weeks, while both groups showed
increased levels of anti-inflammatory cytokines, as IL-4 and
IL-10 [14]. The differential profile of cytokines expression
during sepsis suggests that partially different pathways could
be involved in the initial trigger of the sepsis process at differ-
ent gestational ages.
It has been proposed that, following the release of proin-
flammatory cytokines, several oxidative stress-related path-
ways are activated through different mechanisms, triggering
the initiation of a self-maintaining “sepsis redox cycle,”
finally leading to cell oxidative damage and mitochondria
impairment [9]. According to this model, the cytokine-
induced activation of nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) constitutes the first step
of the process [9]. Several observations are consistent with
NF-κB activation during neonatal sepsis [15, 16], and in a
mouse model of group B Streptococcus neonatal sepsis, the
pathway mediated by c-Jun N-terminal kinase was demon-
strated to play a pivotal role in the orchestration of inflam-
mation during sepsis, as its inhibition significantly
suppressed proinflammatory cytokines production [17].
Similarly, it was recently demonstrated that protein kinase
D is essential for NF-κB pathway activation during group B
Streptococcus sepsis [18]. NF-κB acts as a powerful transcrip-
tion factor which binds to DNA and activates the transcrip-
tion of several different genes including inducible nitric
oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) [8,
9], leading to increased production of nitric oxide (NO)
and superoxide, respectively [9]. Superoxide levels are further
increased by the cytokine-induced direct activation of
NADPH oxidase [9]. In a cardiomyocyte model of neonatal
sepsis, challenge with Gram-negative lipopolysaccharide
(LPS) induced NADPH overexpression, leading to COX-2
overexpression through a MAP-kinase/NF-κB-dependent
mechanism [19]. Therefore, both direct activity of NADPH
oxidase and NADPH-induced COX-2 upregulation can con-
tribute to increase cytoplasmic superoxide [6]. Superoxide is
then dismutated to H2O2 by cytoplasmic CuZn-superoxide
dismutase (SOD) [6]. In a neonatal mouse model of sepsis-
induced lung injury, LPS-induced lung cytokines expression,
neutrophils influx, and NF-κB translocation were suppressed
in NADPH oxidase-deficient animals [20]. Consistent with
these observations, also LPS-induced matrix metallopro-
teinase expression was reduced, as well as alveolar adverse
remodeling characterized by reduced number of alveoli
and complexity of lung alveolarization [20]. These obser-
vations suggest that NADPH oxidase may play a key role
in determining the disruption of lung architecture, typical
of bronchopulmonary dysplasia (BPD) [21] in septic pre-
term newborns.
Increased levels of NO were demonstrated in neonatal
sepsis [22, 23]. Particularly, preterm newborns< 27 weeks
of gestational age presented lower basal levels of NO in
comparison to more mature patients, but produced larger
amounts of NO during the first 2 days of bacteremia, suggest-
ing that both the basal production of NO and the modulation
of NO production may be related to gestational age [23]. In a
cohort of term or near term newborn with EOS, circulating
NO was significantly higher in comparison to controls [24].
Moreover, iNOS-deficient mice model presented lower
degree of inflammation following exposure to Escherichia
coli [25], and iNOs overexpression was also demonstrated
by real-time PCR in neonatal respiratory epithelial cells
challenged with Staphylococcus aureus and Staphylococ-
cus epidermidis, together with proinflammatory cytokines
upregulation [26].
NO, along with ROS, directly inhibits electron transport
chain in the mitochondria [27, 28], resulting in impaired
energy production and accumulation of mitochondrial
superoxide [9, 27, 28]. Mitochondrial dysfunction was
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demonstrated to be the central core of deleterious proinflam-
matory and prooxidant routes in adult sepsis [8]. Within the
mitochondrion, superoxide can react with NO to produce
peroxinitrite, which in turn decomposes to hydroxyl radical
and nitrogen dioxide [9]. These highly reactive species fur-
ther affect mitochondrial functionality [9], and in cellular
model of neonatal sepsis, peroxinitrite was shown to suppress
mitochondrial function [29], thus favoring the maintenance
of a detrimental pathway within the mitochondrion itself.
Alternatively, superoxide anion derived by dysfunctional
electron transport chain (ETC) can undergo dismutation to
H2O2 by MnSOD within the mitochondrion, which is then
released in the cytosol [9]. Therefore, as a result of NADPH
oxidase activity, COX-2 overexpression, and dysfunctional
mitochondrial ETC, increasing amounts of H2O2 accumu-
late in the cytosol and activate NF-κB, thus completing a
detrimental self-maintaining redox loop [9].
In preterm newborns, oxidative pathway activation
during sepsis would interact with a preexisting prooxidant
state. Increased ROS production was demonstrated in
preterm newborns, resulting from hyperoxic events and
mechanical ventilation [30–32], and prematurity is well
known to be associated with increased risk of oxidative
stress-related diseases, as BPD and retinopathy of prematu-
rity [31]. On the other hand, impaired antioxidant capacities
were demonstrated in preterm newborns, both because of
inappropriate interruption of placental-fetal transfer of anti-
oxidant molecules and insufficient endogenous production
[32]. In fact, fetal levels of antioxidant enzymes (AOEs) as
SOD, catalase (CAT), glutathione peroxidase (GPx), and glu-
tathione reductase (GR) progressively increase during gesta-
tion, paralleling the maturation of surfactant system and
preterm animal models fail to induce SOD and GPx in
response to oxidative challenges [33, 34], in contrast to term
newborns, who were demonstrated to induce AOEs in case
of fetal distress [35] or resuscitation with high FiO2 [36].
The imbalance of the redox status favoring prooxidative
pathways in preterm newborns during sepsis could also be
implicated in the pathogenesis of BPD and of the long-
term neurodevelopmental sequelae observed in this popula-
tion following a septic event [37]. Despite the exact pathoge-
netic mechanisms leading to long-term adverse outcomes in
septic newborns remain to be elucidated, it has been pro-
posed that both direct increase in oxidative burden and
activation of apoptosis would play a major role in tissue
impairment [8]. During ongoing development of the central
nervous system, a fall in ATP levels and an increase of
prooxidant species, resulting from deleterious redox cycles,
would critically affect the functionality and permeability of
the mitochondria [38]. Particularly, the release of cyto-
chrome c from the mitochondria to the cytosol would
activate apoptosis through caspase-mediated signaling path-
ways [39]. Noticeably, caspases, elements of the proapopto-
tic Bcl-2 family, and the apoptotic protease activating
factor 1 were demonstrated to be overexpressed in neonatal
brain tissue in comparison to adult brain tissue [39], indicat-
ing preferential activation of proapoptotic pathways in
newborns following a noxious stimulus. Oligodendrocyte
progenitors and subplate neurons, which are the cell species
predominantly involved in the pathogenesis of white matter
injury and periventricular leukomalacia in newborns, were
proved particularly vulnerable to oxidative stress [40, 41].
Apoptosis of such cell species would also be implicated in
the occurrence of visual impairment, as it would detrimen-
tally affect the development of the optic nerve and of the
visual cortex [40, 42]. Analogously, oxidative damage and
apoptosis have been proposed to be involved in the patho-
genesis of long-term respiratory morbidities, as BPD, since
increased oxidative burden and exaggerated aspects of apo-
ptosis were demonstrated in newborns with respiratory dis-
eases [43–45]. In lung tissue, activation of apoptosis would
result in arrest of the normal process of alveolarization,
which is the typical lesion of new BPD [21].
Despite mitochondrial impairment has not been specifi-
cally investigated in the newborn, such mechanism could be
relevant in the setting of neonatal sepsis. In animal models,
neonatal endotoxemia was associated with impairment of
carnitine palmitoyltransferase I, the enzyme that controls
the entry of fatty acids into the mitochondrion and the rate
of fatty acid oxidation, in the developing heart and kidney
[29]. The activity of the enzyme measured in mitochondria
isolated from the heart, but not from the kidney, of septic
newborn rats was significantly impaired, likely because of
deleterious effects of ROS on ETC [29]. Moreover, treatment
with glutamine, an antioxidant agent that increases Krebs
cycle intermediates and supports oxidative phosphorylation,
was proved effective in reducing the circulating levels of
TNF-alpha and IL-10 in newborn rats exposed to LPS,
although it exerted no effect on lipid peroxidation markers
and NO production [46]. These results are consistent with
the previous observation of restored mitochondrial ultra-
structure following exposure to glutamine treatment in a
cellular model of neonatal sepsis [47]. The aspect of mito-
chondrial dysfunction during sepsis could be of major
importance in the population of preterm newborns, as they
exhibit differential basal mitochondrial functionality in com-
parison to term newborns [48]. Particularly, the activity of
complex III and IV of respiratory chain, pyruvate dehydroge-
nase and citrate synthase measured on muscle mitochondria
obtained from autopsy, was proved to be markedly lower in
preterm newborns in comparison to older children, suggest-
ing an age-dependent functionality of mitochondrial respira-
tory chain [48], which would expose more preterm newborns
to an increased risk of energy deficit, and thus organ failure,
particularly in case of superimposed mitochondrial impair-
ment during sepsis.
2.2. Markers of Oxidative Stress and Antioxidant Defense.
The profile of circulating markers of oxidative stress and of
enzymatic and nonenzymatic antioxidant defenses during
neonatal sepsis has been less extensively studied in compari-
son to adult patients (Table 1). In septic newborns, circulat-
ing levels of TNF-alpha and malondialdehyde (MDA), a
common marker of polyunsaturated fatty acid peroxidation,
were shown to be significantly increased in comparison to
healthy controls [49, 50] along with antioxidant enzymes
xanthine-oxidase, SOD, and GPx, while peroxidase and uric
acid levels were suppressed [49]. Moreover, GPx in the subset
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of newborns with septic shock was significantly higher than
in patients with sepsis but no septic shock [49], suggesting
a preferential hyperactivation of antioxidant pathways
related to glutathione during septic shock. In 44 newborns
with sepsis, MDA, SOD, GPx, and CAT were significantly
increased in comparison to controls, while uric acid and
albumin levels were significantly reduced [51], and similar
changes were also observed in those newborns who died
because of sepsis in comparison to survivors [51].
These data are consistent with the activation of prooxi-
dant pathways and ROS overproduction during sepsis, paral-
leled by an increased activity of antioxidant defense systems,
which, however, cannot cope with increased oxidative
burden, resulting in detrimental cellular effects, as demon-
strated by increased markers of oxidative damage [49]. In
accordance with these observations, in a neonatal sepsis
model obtained by cecal ligation and perforation (CLP) in
piglets, total hydroperoxide (TH) and biological antioxidant
potentials (BAP) were both increased 1 hour after the proce-
dure in comparison to sham animals, and BAP remained
significantly higher during the 6-hour study period [52].
The increase of TH and BAP was paralleled by a significant
increase of TNF-alpha and IL-6 in septic animals in compar-
ison to controls, and a positive correlation was observed at
1-hour post-CLP between TH and BAP, TH and TNF-
alpha, and BAPs and IL-6 [52], suggesting mutual interac-
tions between inflammatory pathways and oxidative stress
during neonatal sepsis. Consistent with these data, more
recently, excessive ROS production was directly demon-
strated by DCF fluorescence technique in vital section of
renal cortex of newborn rats exposed to LPS [53].
In a cohort of 120 preterm newborns with mean gesta-
tional age of 31 weeks, including 20 patients with proven
EOS, 20 patients with highly probable EOS, and 80 unin-
fected controls, oxidative stress and inflammatory markers
in cord blood samples were proved to be significantly higher
in septic patients versus controls [54]. Particularly, both pro-
tein carbonyls, a marker of protein oxidation, and thiobar-
bituric acid reactive species (TBARS), a marker of lipid
peroxidation, were increased along with IL-6 and IL-10
levels in patients with sepsis, both proven or clinically highly
probable, in comparison to controls, and in patients with
proven sepsis in comparison to controls [54]. Only TBARS
and IL-6, but not the other markers, were significantly
increased in the group of proven sepsis versus highly proba-
ble sepsis [54]. According to ROC curve analysis, TBARS
and IL-6 showed the best performance for the diagnosis of
EOS among the studied markers with an area under the
curve of 0.88. Multivariate logistic analysis comparing
TBARS and IL-6 showed that TBARS is a better predictor
of EOS and TBARS was the only marker independently
associated with EOS [54]. TBARS and IL-6 levels in preterm
newborns also showed a mild to moderate correlation with
clinical sepsis severity score, although no correlation was
demonstrated between these markers and sepsis-related
mortality [55]. As some markers of oxidative stress, along
with indicators of antioxidant defense, are available as
point-of-care test (POCT), the confirmation of a relation-
ship between oxidative stress markers and sepsis severity
would be of major relevance in critical care settings. Partic-
ularly, available or under development POCTs for oxidative
stress and antioxidant status include free oxygen radicals
test [56, 57], free oxygen radicals defense test [56, 57],
8-hydroxy-2′-deoxyguanosine [58], 3-nitrotyrosine [59],
CuZn SOD [60], BAP, measured as capacity of reduction
of ferric to ferrous ions [57], and iridium-reducing assay,
particularly sensitive to GSH [61]. Despite at present
these POCTs have been studied in the adult population,
they would offer several advantages for critically ill new-
borns, as timely manner stratification of sepsis severity and
identification of a patient who would particularly benefit
from antioxidant strategies, the need for small blood
samples, and the possibility to monitor the response to anti-
oxidant treatment. At present, no relationship has been
established between oxidative stress markers and the devel-
opment of long-term adverse outcomes in septic newborns;
however, some biomarkers of inflammation, as S100B,
adrenomedullin, and neuron-specific enolase, were proved
to be also markers of neonatal brain damage [62]. Moreover,
cord blood levels of oxidative stress markers were related to
free radical-related diseases, including IVH, in preterm
newborns [31], indicating that studies are needed in order
to assess whether early markers could predict long-term
outcome in septic newborns.
In a small cohort of septic term newborns, pretreatment
levels of lipid peroxidation-derived aldehydes, MDA and
4-hydroxylalkenals (4-HDA), were demonstrated to be
roughly 2-folds higher than in healthy controls [63]. In 52
newborns with LOS and mean gestational age of 35-36
weeks, plasma lipid peroxidation markers and protein car-
bonyls were proved to increase significantly in patients with
proven or clinical sepsis in comparison to uninfected con-
trols [64]. The study of erythrocyte selenoenzymes showed
increased GPx levels in patients with clinical sepsis and
reduced thioredoxin reductase levels in patients with
proven sepsis in comparison to controls [64], demonstrat-
ing differential regulation of antioxidant selenoenzymes
during sepsis. SOD and CAT were increased in septic
patients, demonstrating an adaptive antioxidant response
to oxidative stress during sepsis, while erythrocyte selenium,
erythrocyte glutathione, and selenoprotein P, the main
plasma selenoprotein, were markedly decreased in patients
with proven or clinical sepsis in comparison to controls,
suggesting consumption of selenium-containing antioxidant
molecules [64].
According to the available evidence, in neonatal sepsis,
both oxidative stress-related pathways and antioxidant
defenses appear induced; however, redox unbalance favoring
oxidative stress likely occurs, as markers of oxidative damage
are increased in comparison to controls [49, 50]. Concordant
with this observation, in 70 newborns with mean gestational
age of 36 weeks, total oxidant state (TOS) and total antioxi-
dant state (TAS) were both increased in septic patients in
the pretreatment period versus controls and oxidative stress
index (OSI), and the percentage ratio of TOS/TAS, was also
increased [65], confirming the prevalence of oxidative stress
pathways on antioxidant defense. TOS and TAS were also
studied to monitor treatment and significantly decreased
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after treatment in septic patients in comparison to pretreat-
ment levels. Moreover, paraoxonase-1 (PON-1), an enzyme
located in HDL inhibiting lipoprotein oxidation in LDL
[66], which is reduced in adult sepsis [67], appeared signifi-
cantly lower in septic newborns before treatment in compar-
ison to controls and also to posttreatment levels [65]. In
septic patients after treatment, higher TAS levels were
observed in comparison to controls, while TOS and PON-1
did not significantly differ, suggesting that compensatory
antioxidant defense might continue beyond the initial oxida-
tive burst. In contrast with these findings, in a cohort of pre-
term newborns with mean gestational age of 34 weeks, no
differences in erythrocyte GPx, GR, and CAT were detected
between septic patients and controls during the clinical
course of sepsis, although in septic patients at 60 days, CAT
activity was significantly increased in comparison to controls
and GPx activity depressed in comparison to day 0 [68].
Chorioamnionitis is a well-known risk factor for fetal and
neonatal infection, especially in preterm newborns, as about
5–17% of preterm newborns whose mother has chorioam-
nionitis develop EOS [69, 70]. In preterm newborns with
gestational age < 30 weeks, oxidative stress markers, as iso-
prostanes, nonprotein-bound iron, and advanced oxidative
protein products were proved to be significantly increased
in cord blood of newborns of mothers with histological
chorioamnionitis in comparison to the control group [71].
Moreover, a significant positive correlation was found in
multivariate analysis adjusted for the main neonatal and
perinatal variables between histological chorioamnionitis
and cord levels of oxidative stress markers, indicating
increased fetal oxidative burden during intra-amniotic infec-
tion [71]. Moreover, increased levels of oxidative markers as
prolidase, matrix metalloproteinases, TOS, and OSI were
demonstrated in vaginal washing fluid of healthy pregnant
women with preterm premature rupture of membranes
(PPROM) in comparison to controls with intact membranes,
while antioxidant parameters, as PON-1 and total antioxi-
dant capacity (TAC), were significantly lower [72]. More-
over, prolidase, matrix metalloproteinases, and oxidative-
antioxidant status parameters significantly differed in women
with chorioamnionitis in comparison to those without chor-
ioamnionitis in the PPROM group and levels of prolidase,
matrix metalloproteinase-13, TOS, TAC, and PON-1 were
proved to predict chorioamnionitis in the PPROM group
[72]. These results are partially discordant with the observa-
tion of measurable amount of oxidative stress markers in
amniotic fluid in 183 pregnant women with PPROM but
the absence of influence of intra-amniotic infection or histo-
logical chorioamnionitis on the levels of oxidative stress and
antioxidant biomarkers [73]. Concordantly, intra-amniotic
infection, histological chorioamnionitis, and funisitis did
not significantly affect cord blood TAC, ferric reducing anti-
oxidant power, TBARS, advanced glycation end products,
and markers of oxidative stress in the offspring of 165
pregnancies complicated by PPROM [74]. On a whole,
despite increased fetal and oxidative burden could occur
as a result of PPROM and chorioamnionitis, although
mixed results were reported, at present, no conclusions
can be derived regarding its role in neonatal sepsis, as
no data on oxidative balance are available for the subset
of newborns who develop EOS as a consequence of
maternal chorioamnionitis.
2.3. Intestinal Microbiota and Oxidative Stress. The gastroin-
testinal system was recently demonstrated to take part in the
oxidative burst during sepsis in preterm newborns, providing
evidence that host-microbiota interactions could be of major
importance under septic conditions [75]. Fecal samples of 5
pairs of twins with mean gestational age of 30 weeks, each
pair including one septic and one control twin, were used
for microbiota analysis and genome-wide expression analysis
on exfoliated intestinal cells. Induction of several genes
involved in proinflammatory and prooxidant pathways was
demonstrated in intestinal cells of septic newborns in com-
parison to controls, and such genome expression changes
were paralleled by microbiota shift towards predominance
of Enterobacteria with reduction of Bacteroides and Bifido-
bacteria, likely resulting from oxidative stress and low-
grade inflammation in the gut mucosa [75]. A significant
inverse correlation was observed between Bacteroides and
Bifidobacteria and 8 genes involved in oxidative stress, and
also further genes involved in TNF-alpha and IL-1beta
signaling pathways [75]. These results were in agreement
with a previous study of blood genome-wide expression
profile in very low birthweight (VLBW) infants, demonstrat-
ing overexpression of genes involved in innate immunity and
inflammation in septic patients in comparison to controls
[76]. These aspects could be of major importance in the pop-
ulation of preterm newborns, who exhibited basal overex-
pression of genes related to inflammation in the gut in
comparison to term newborns, as demonstrated by whole
genome sequencing of stool-derived mRNA [77], and over-
expressed in septic condition pathways related to IL-1 recep-
tor kinase 2, fibroblast growth factor receptors, gap junctions,
and cell division regulators [78]. Moreover, in a preterm pig
model of necrotizing enterocolitis (NEC), the study of intes-
tinal proteomics demonstrated that antibiotic treatment
induced several beneficial mucosal pathways, including anti-
oxidant ones, as CAT activity was significantly increased in
comparison to untreated animals, suggesting that antibiotic
treatment during NEC is associated to a more favorable
redox profile, shifting towards antioxidant prevalence [79].
Intestinal microbiota has recently become a central
component of the sepsis process in preterm newborns as
the disruption of physiological intestinal colonization
induced by aggressive antibiotic treatment was proved to
favor the development of pathogen species and to be associ-
ated with adverse outcomes [80, 81]. Early empirical antibi-
otics administered for more than 5 days, without evidence
of positive blood culture, was positively associated to
increased risk of NEC and death in a large cohort of ELBW
infants [82] and to increased incidence of LOS and of the
combined outcome LOS-NEC-death in 365 VLBW infants
[83]. It was hypothesized that high levels of circulating proin-
flammatory and prooxidant mediators observed in septic
newborns, through an inflammatory organ cross-talk, may
affect gut mucosa gene expression profile, leading to local
environment inflammation and oxidative stress that, in
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turn, would affect microbial colonization, favoring pathogen
species [75].
As antibiotics are one of the milestones of medical treat-
ment of NEC but inappropriate antibiotic courses are related
to adverse outcomes, the optimal antibiotic regimen for
patients with NEC is of crucial importance in clinical settings
[84, 85]. Two recent surveys reported high variability among
different centers and within single centers in antibiotic treat-
ments for NEC in terms of type and number of antibiotics
and duration of treatment [84, 85]. Despite the most fre-
quently reported regimen was the association of amoxicillin
or ampicillin, gentamycin, and metronidazole [84, 85] basing
on old data [86], the criteria to broaden antibiotic spectrum
were variable among practitioners and for surgical patients,
the duration of postsurgery antibiotic course was not stan-
dardized [85]. Twometa-analyses found insufficient evidence
to make specific recommendations on the most appropriate
type and duration of antibiotic treatment [87, 88]; therefore,
specifically designed studies should be performed to address
the optimal antibiotic regimen for patients with NEC in
terms of harm/benefit ratio.
Finally, different antioxidant treatments were suggested
to be effective in the prevention of NEC development in
preterm newborns. Particularly, oral supplementation with
lactoferrin was proved to reduce NEC occurrence in a
meta-analysis [89, 90], although this evidence had low-to-
moderate quality [91] and human recombinant lactoferrin
was administered only in one study, while bovine lactoferrin
was used in all the others [91]. The beneficial effect of lacto-
ferrin in preserving the gut mucosa integrity is likely related
to the position of lactoferrin itself on the mucosal surface,
where it contrasts microbial invasion and translocation
across the intestinal wall [91]. On the other hand, pentoxifyl-
line administration showed mixed result, and in meta-analy-
sis, did not affect NEC occurrence [92]. However, because of
the low quality of evidence, specific trials investigating pen-
toxifylline treatment for NEC prevention and treatment are
advocated [92]. N-Acetylcysteine administration in a rat
model of NEC reduced gut oxidative stress damage measured
as MDA, gut abnormalities, and intestinal levels of TNF-
alpha, while was proved to increase local activity of antioxi-
dant enzymes [93]. Finally, also melatonin was hypothesized
to confer protection against NEC development, due to its
pleiotropic and multiorgan antioxidant activities [94]; how-
ever, its potential usefulness in NEC prevention remains at
present to be assessed by clinical trials.
3. Antioxidant Strategies in Neonatal Sepsis
Basing on evidence of increased oxidative burden in neonatal
sepsis, therapeutic strategies targeting proinflammatory and
prooxidant pathways would be expected to be beneficial;
however, despite promising results in cellular and animal
models, evidence from clinical trials is still limited. In the
neonatal populations, antioxidant treatments investigated
during sepsis include both direct antioxidant administration
and pharmacologic inhibition of prooxidant pathways.
Melatonin demonstrated pleiotropic antiapoptotic, anti-
oxidant, and anti-inflammatory effects in vitro and in vivo,
as direct scavenging activity against ROS and other oxidizing
agents and stimulation of antioxidant enzymes, as CAT,
SOD, GPx, GR, and gamma-glutamylcysteine synthase, the
rate-limiting enzyme in glutathione synthesis [95]. Inter-
estingly, melatonin accumulates within the mitochondria
[95, 96]; therefore, it would possibly target the local excessive
ROS production, which is typical of dysfunctional mitochon-
dria during sepsis [8, 27]. In preterm newborns, melatonin
was demonstrated effective in reducing oxidative stress
markers and inflammatory mediators in RDS and perinatal
asphyxia [97, 98]. In a small cohort of septic term newborns,
oral melatonin treatment within the first 12 hours from
diagnosis (2 doses, 10mg/kg each, administered at 1-hour
interval) significantly reduced lipid peroxidation markers,
MDA+4-HDA, at 1 and 4 hours after treatment [63]
(Table 2). Melatonin-treated infants also showed a significant
reduction in white blood cell count, absolute neutrophil
count, and CRP 24 hours after treatment, while at the same
time untreated septic infants presented stable white blood cell
count and neutrophil count and increased CRP levels. More-
over, while 3 of 10 septic untreated infants died, no cases of
death were observed in the melatonin-treated group [63].
These encouraging results are consistent with a favorable
suppression of prooxidant and proinflammatory pathways
induced by melatonin treatment in neonatal sepsis, occurring
as early as 1 hour after oral administration [63]. Concor-
dantly, in a recent nonrandomized trial including 40 septic
newborns treated with antibiotics and melatonin (20mg/kg,
single dose) or antibiotics alone, melatonin treatment was
associated with a significantly stronger reduction of CRP
levels and improvement of clinical parameters in comparison
to antibiotic treatment alone [99] and it was also shown to
improve clinical sepsis score in comparison to antibiotic
treatment alone in a cohort of 50 septic newborns [100].
These data are also concordant with the observation of bene-
ficial effect of melatonin in newborns in the postsurgery
period, showing reduced nitrite-nitrate and proinflammatory
cytokines levels following melatonin administration in com-
parison to untreated surgical newborns [101]. Interestingly,
higher melatonin levels were demonstrated in septic new-
borns with LOS in comparison to uninfected controls [102],
suggesting that melatonin endogenous production might be
upregulated during sepsis, taking part in antioxidant defense.
Basing on these favorable preliminary data, randomized con-
trol trials are warranted to assess efficacy and safety of mela-
tonin as an adjunct treatment in neonatal sepsis [103].
Promising results in antioxidant treatment for neo-
natal sepsis were obtained with the administration of
pentoxifylline, which exerts several antioxidant and anti-
inflammatory activities, as reduced glutathione level restora-
tion, mitochondrial viability maintenance, inhibition of
TNF-alpha production, preservation of proper endothelial
function and of proper coagulation activity, and prevention
of gastrointestinal vasoconstriction [104]. In a randomized
controlled trial including 120 newborns with LOS and mean
gestational age of 30 weeks, pentoxifylline administration
(5mg/kg/h i.v. for 6 hours for 6 days) was associated with
reduced TNF-alpha and CRP levels, reduced need for
vasopressor, shorter duration of respiratory support and
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antibiotic treatment, shorter hospital stay, lower incidence of
disseminated intravascular coagulopathy, metabolic acidosis,
and thrombocytopenia [105] (Table 2). However, no
differences were observed in mortality and short-term mor-
bidity between pentoxifylline-treated and untreated septic
newborns [105, 106]. In a meta-analysis including 6 small
studies, pentoxifylline administration in septic newborns
was proved effective in reducing all-cause mortality and the
length of hospital stay, and subgroup analysis demonstrated
significantly reduced mortality in preterm infants, in infants
with proven sepsis, and in infants with Gram-negative sepsis
[92], leading to the conclusion that pentoxifylline may
represent a beneficial adjunct treatment in neonatal sepsis,
although larger trials are needed in order to define pentoxi-
fylline efficacy and the safety profile. Interestingly, in vitro
pentoxifylline was recently proved to exert more powerful
anti-inflammatory effects in newborns than in adults [107].
In cord blood and adult blood stimulated with LPS, pentoxi-
fylline treatment suppressed TLR-mediated cytokines levels,
as TNF-alpha and IL-1beta, in a dose-dependent manner
and this effect was more pronounced in cord blood in com-
parison to adult blood [107], suggesting that pentoxifylline
adjunct treatment could be particularly beneficial in the
neonatal population.
Lactoferrin, a normal component of human milk, is an
anti-infective and antioxidant agent, acting through iron
sequestration and direct detrimental effect on pathogen cell
membranes [108]. In a randomized controlled trial including
472 VLBW infants who were randomized to lactoferrin alone
or lactoferrin and probiotics or placebo, the supplementation
with lactoferrin alone or in combination with probiotics
significantly reduced the incidence of LOS, both fungal and
bacterial, in comparison to placebo [109]. Moreover, a recent
meta-analysis including 6 randomized controlled trials
showed that lactoferrin supplementation to enteral feeds in
preterm newborns, alone or in combination with probiotics,
reduced the incidence of LOS and NEC stage II or III,
although overall mortality was not affected [89]. However,
at present, no evidence are available on the possible beneficial
effect of lactoferrin administration during neonatal sepsis;
therefore, further studies are needed to assess whether
lactoferrin could be beneficial not only as a preventive
measure but also as an adjunct treatment for neonatal sepsis
and also to establish the optimal dosing regimen. Interest-
ingly, in 15 preterm newborns, serum lactoferrin levels were
significantly lower in patients with proven sepsis in compar-
ison to those with clinical sepsis and were positively corre-
lated with white blood cell count or absolute neutrophil
count, suggesting that the lowest lactoferrin observed in
more immature infants is likely related to suboptimal white
cell activity and that lactoferrin supplementation could be
particularly effective in this population [110].
Vitamin E, which acts primarily as circulating direct anti-
oxidant, has been extensively investigated for the prevention
of prematurity-related mortality and morbidity and was
proved effective in reducing the incidence of intracranial
bleeding and retinopathy of prematurity in the subset of
VLBW infants in a meta-analysis including 26 randomized
Table 2: Main evidence from clinical studies on melatonin and pentoxifylline treatment in neonatal sepsis.
Enrolled population Interventional procedure Outcomes Ref.
Melatonin
30 newborns:
10 sepsis/10 sepsis and melatonin
treatment/10 controls
Melatonin, 20mg/kg orally within 12 hours
of sepsis diagnosis (2 doses, 10mg/kg each,
separated by 1-hour interval)
Reduced MDA+4-HDA at 1 and 4 hours after
treatment in septic treated versus septic
untreated infants
Reduced WBC count, ANC, CRP 24 hours after
treatment in septic treated versus septic
untreated infants
[63]
40 newborns:
20 sepsis/20 sepsis and
melatonin treatment
Melatonin, 20mg/kg orally, single dose
Reduced CRP and better clinical improvement at 24
and 72 hours after treatment in treated versus
untreated infants
[99]
50 newborns:
25 sepsis/25 sepsis and
melatonin treatment
Melatonin, 20mg/kg orally, single dose
Reduced sepsis score at 24 and 48 hours after
treatment in treated versus untreated infants
[100]
Pentoxifylline
120 newborns:
60 LOS/60 LOS and
pentoxifylline treatment
Pentoxifylline, 5mg/kg/h IV for 6 hours
for 6 days
Reduced TNF-alpha, vasopressor need, duration of
respiratory support, duration of antibiotics, hospital
stay, incidence of DIC, and thrombocytopenia in
treated versus untreated infants
No differences in mortality
[105]
Meta-analysis of 6 randomized
or quasi-randomized trials;
416 newborns
Pentoxifylline, continuous IV infusion,
different dosing regimens
Reduced all-cause mortality, reduced hospital stay
in septic treated versus untreated septic infants
Reduced mortality in the subgroup of preterm
newborns, proven sepsis, and Gram-negative sepsis
in septic treated versus untreated septic infants
[106]
MAD: malondialdehyde; 4-HDA: 4-hydroxylalkenals; WBC: white blood cell; ANC: absolute neutrophil count; CRP: C-reactive protein; DIC: disseminated
intravascular coagulopathy; LOS: late-onset sepsis.
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controlled trials [111]. However, vitamin E supplementation
was associated with increased risk of sepsis both in the
case of intravenous and nonintravenous administration
and serum tocopherol levels higher than the cut-off of
3.5mg/dL were positively associated with increased risk
of sepsis [111], leading to the conclusion that routine vita-
min E supplementation in preterm newborns cannot be
recommended. In a recent randomized open-label study
including 65 preterm newborns with mean gestational age
of 34 weeks, vitamin E supplementation reduced GPx activity
at 30 days in septic newborns in comparison to untreated
septic newborn although it also mitigated the reduction of
GPx observed in septic patients 60 days after sepsis onset
[68]. Moreover, vitamin E supplementation suppressed GR
activity in treated septic patients, while increased GPx
activity in controls in comparison to untreated controls
[68]. The combination of direct scavenging effect of vitamin
E with increased GPx activity would result in enhanced
H2O2 removal with a reduction in efficiency of circulating
pathogen discharge and therefore would explain the
increased risk of sepsis observed in vitamin E-
supplemented newborns [68, 111].
Other antioxidant measures with potential efficacy in
neonatal sepsis that have been investigated in clinical settings
include selenium [112] and zinc supplementation [113], and
treatment with ibuprofen [114].
Edaravone (3-methyl-1-phenyl-pyrazolin-5-one), a free
radical scavenger introduced in the latest years in experimen-
tal settings, exerts multiple antioxidant effects, as hydroxyl
radical scavenging, suppression of hydroxyl-dependent lipid
peroxidation, and electron donation to ROS [115], leading
to beneficial effects in animal models of neonatal hypoxic-
ischemic encephalopathy [116]. In a piglet model of neonatal
sepsis, edaravone was demonstrated to reduce TH levels 1
hour after CLP and nitrite-nitrate levels at 3 and 6 hours in
comparison to septic untreated animals, indicating favorable
antioxidant effects [117] (Table 3). These changes were
paralleled by clinical improvement of septic animals, as
demonstrated by higher cardiac output and mean arterial
pressure, lower heart rate, and longer survival time in treated
versus untreated animals, suggesting possible beneficial
effects of edaravone on sepsis clinical course in the newborns
[117]. Furthermore, edaravone delayed TNF-alpha surge in
treated animals and also prevented the increase of high
mobility group box 1 (HMGB-1), a nuclear transcription fac-
tor involved in the systemic inflammatory response [117]. In
the same animal models, edaravone was also proved effective
in reducing sepsis-related pulmonary hypertension and the
ratio between mean pulmonary and systemic arterial pres-
sure was positively related to TNF-alpha levels, suggesting
that edaravone may exert suppressive action on TNF-alpha
release [118]. In a small cohort of pediatric patients with
cerebral infarction, edaravone was recently associated with
improved neurological outcome without significant adverse
effects [119].
The endothelin system is well known to be involved in
sepsis, as endothelin-1 (ET-1) induces activation of NF-κB-
mediated proinflammatory pathways and expression of
adhesion molecules [120] and ET-1 levels appear increased
in septic newborns, particularly in case of pulmonary hyper-
tension [121, 122]. The infusion of endothelin receptor
antagonist ETR-P1/fl was proved effective in reducing serum
nitrite and nitrate, TNF-alpha, and HMBG-1 in a piglet
model of neonatal sepsis and also in reducing pulmonary
hypertension and increasing mean arterial pressure and
survival time [123] (Table 3). In accordance with this study,
in the same animal model, treatment with ETR-P1/fl reduced
TH, OSI (calculated as total hydroperoxide/biological antiox-
idant potentials), and IL-6 at 3 and 6 hours after CLP,
indicating attenuation of prooxidant and proinflammatory
insult [124]. At present, endothelin receptor antagonists have
never been investigated in clinical settings in the newborn.
As dysfunctional mitochondria are the key factor of
organ impairment during sepsis [8, 28], mitochondrial-
targeted antioxidant treatment has been studied in preclinical
models of adult sepsis [125]. In order to achieve antioxi-
dant protection of mitochondria, potential useful strategies
include the administration of ROS scavengers, which specif-
ically target the mitochondria and act where needed within
the mitochondria, or the induction of endogenous mitochon-
drial antioxidant system [125]. Particularly, the main studied
agents are obtained by conjugation of antioxidant molecules
Table 3: Animal studies of novel antioxidant treatments in neonatal sepsis.
Model Interventional procedures Outcomes Ref.
Edaravone
Piglets
CLP alone or CLP and IV continuous
edaravone infusion
Reduced TH at 1 hour after CLP, reduced nitrite-nitrate at 3 and 6 hours, reduced
HMGB-1, delayed TNF-alpha surge, increased mean arterial pressure, reduced
heart rate, longer survival time in treated versus untreated animals
[117]
Piglets
CLP alone or CLP and IV continuous
edaravone infusion
Reduced pulmonary hypertension in treated versus untreated animals
Mean pulmonary artery pressure/mean systemic arterial pressure ratio positively
related to TNF-alpha levels
[118]
Endothelin-1 receptor antagonist
Piglets
CLP alone or CLP and IV continuous
ETR-P1/fl infusion or controls
Reduced nitrite-nitrate, TNF-alpha, HMBG-1, reduced pulmonary hypertension
in CLP-treated animals versus CLP alone
[123]
Piglets
CLP alone or CLP and IV continuous
ETR-P1/fl infusion or controls
Reduced TH, OSI, IL-6 at 3 and 6 hours post-LP [124]
CLP: cecal ligation perforation; TH: total hydroperoxide; OSI: oxidative stress index; HMGB-1: high mobility group box 1.
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to lipophilic cations that accumulate in the mitochondria,
driven by mitochondrial membrane potentials, as MitoQ,
containing ubiquinone antioxidant moiety, or by the
conjugation of fragment of antibiotic with the stable nitrox-
ide radical TEMPOL, that is able to accept electrons from
unstable ROS, to dismute superoxide anion, and to exert
catalase-like activity [125]. Other strategies under investiga-
tion include the administration of small synthetic peptides
(SS peptides) with scavenger activity, which selectively con-
centrate in the mitochondria, and potentiation of endogenous
mitochondrial antioxidant defenses by the administration of
N-acetyl-l-cysteine, which accumulates in the mitochondria
and increases local glutathione availability or by genetic
approaches, as adenoviral transfection with MnSOD [125].
At present, none of these strategies has been studied in
models of neonatal sepsis; therefore, mitochondrial-targeted
antioxidant treatment could represent a potential future line
of research in the field of neonatal sepsis.
4. Conclusions
Oxidative stress, along with proinflammatory pathways, was
demonstrated to play a major role in neonatal sepsis both
in vitro and in vivo. However, few evidences are available at
present on the clinical usefulness of adjunct antioxidant
treatment in neonatal sepsis.
Some relevant limitations of the studies investigating
oxidative stress and antioxidant treatments in neonatal sepsis
may partially limit the quality of the available evidence. Most
of the studies assessing antioxidant enzyme activity in neona-
tal sepsis were based on serum measurements that could be
influenced by hemolysis processes and in fact provided
partially different evidences in comparison to observations
based on erythrocyte level measurements [68]. Moreover,
data obtained from animal studies on oxidative stress
markers or antioxidant treatments in neonatal sepsis may
not strictly reflect the clinical conditions of septic newborns,
as in experimental settings, the animal models are challenged
with high levels of LPS or bacteria, which is often not the case
in clinical practice [52, 53, 117, 118, 123, 124]. As regard to
clinical observations, not all of the studies reported rigorous
inclusion criteria, defining whether both EOS and LOS or
only one of the two categories is included; therefore, conclu-
sions derived from these studies could be misleading as redox
pathophysiology of EOS and LOS could be partially different.
Moreover, while some studies included only culture-proven
sepsis, others included both proven and clinical sepsis, and
others did not specify this aspect. However, due to the fact
that several nonsepsis-related perinatal variables could affect
oxidative stress in newborns, only data coming from proven
sepsis patients should be considered fully reliable, while those
coming from clinical sepsis patients could merely reflect the
effect of different conditions activating oxidative stress
pathways. Finally, clinical studies investigating the usefulness
of antioxidant treatments in neonatal sepsis often lack strict
randomization, leading to evidences that, although promis-
ing, need to be confirmed by properly designed studies.
Despite several limitations, available evidence suggests
that oxidative stress processes are activated during neonatal
sepsis, posing the basis for the potential clinical usefulness
of antioxidants as an adjunct strategy for the treatment of
septic newborns. Antioxidants, in fact, would counterbalance
the detrimental prooxidant cycle in newborn sepsis, which,
once initiated, proceeds independently from the pathogens
themselves and thus is not affected by antibiotic treatment
alone. Further studies are needed to identify useful agents
and to standardize antioxidant treatment in neonatal sepsis.
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